-The Times of India About 38 million people in India (which is more than Canada's population) fall below the poverty line every year due to healthcare expenses, of which 70% is on purchase of drugs. Yet, the much-awaited drug price control order (DPCO) 2013, meant to control the price of medicines does not cover over 80% of the medicines in the market. Many drugs crucial for India's disease profile have been...

-The Economic Times NEW DELHI: Getting better is getting cheaper. The new drug price policy, the first after 18 years and expected to fully come into effect over the next six months, will reduce average middle class household spend on medicines by over 20%. For some crucial medicines, savings could be as much as 50% or more. The drug price regulator is crunching numbers to measure the impact of the new pricing...

-The Hindu The huge deficit in blood availability outside urban centres must jolt the government into legalising unbanked blood supply Twenty-year-old Putul, living in a village 70 km from a district headquarters town in Chhattisgarh, had been in labour for two days and a night. It was her first pregnancy. In order to hasten labour, the local quack administered several injections that increased her uterine contractions. Forty hours after the onset of...

-The Hindu     The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...

-The Hindu The current market prices are essentially over and above the actual cost of production - a difference that could run from 100 per cent to 5,600 per cent, depending upon various therapeutic categories In a liberalised market economy, do we need price controls on drugs? Policymakers and the pharmaceutical industry do not think so. They believe that price controls are an inefficient tool that distorts resource allocation, squeezes revenue, reduces...